Medical device hemolysis testing is a critical biocompatibility evaluation that assesses the potential of device materials to damage red blood cells and release hemoglobin into plasma. This test is essential for any device that contacts circulating blood, directly or indirectly, and is required under ISO 10993-4 standards for regulatory submissions worldwide. Understanding the testing methodology, sample requirements, and acceptance criteria helps manufacturers ensure patient safety and streamline market approval.
Technical Overview
Hemolysis testing for medical devices evaluates the extent to which device materials or extracts cause the destruction of red blood cells (erythrocytes) and the subsequent release of hemoglobin into the surrounding plasma or serum. When medical devices come into contact with blood—whether through direct circulation contact, indirect contact, or leachable substances—the materials may induce mechanical damage or chemical toxicity to erythrocyte membranes. This damage results in hemolysis, which can lead to serious clinical consequences including anemia, hemoglobinuria, jaundice, and kidney damage.
The hemolysis test is a key component of the biological evaluation of medical devices as specified in ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood). This standard categorizes blood-contacting devices into three categories based on the nature of blood contact: non-contact devices, indirect contact devices (e.g., cannulas, catheters used for fluid transfer), and direct contacting devices (e.g., oxygenators, dialyzers, hemoadsorbents). The hemolysis test is applicable to devices in the latter two categories where blood contact is expected or possible.
The fundamental principle of the hemolysis test involves exposing either diluted anticoagulated rabbit or human blood (or extracts of the test material) to controlled conditions, then measuring the amount of free hemoglobin released. The degree of hemolysis is expressed as a percentage, calculated by comparing the hemoglobin concentration in the test sample against positive and negative controls. The negative control typically consists of a material known to be non-hemolytic, while the positive control is a substance known to cause complete hemolysis, such as sterile water for injection or a detergent solution.
Testing Samples
Blood-Contacting Medical Devices
Devices that directly contact circulating blood represent the primary category for hemolysis testing. These include extracorporeal circulation devices such as oxygenators (membrane lungs), hemodialyzers, blood pumps, blood filters, and hemoperfusion cartridges. Additionally, intravascular catheters such as central venous catheters, percutaneous transluminal coronary angioplasty (PTCA) catheters, guidewires, and stents require hemolysis evaluation. Artificial heart valves, ventricular assist devices, and vascular grafts also fall under this category.
Indirect Blood-Contacting Devices
Devices that contact blood indirectly through fluid pathways or temporary contact also require hemolysis assessment. These include infusion sets, transfusion sets, syringes, stopcocks, extension tubes, and drug delivery devices where the administered fluid will subsequently contact blood. The evaluation typically involves extracting leachable substances from the device and exposing them to blood.
Sample Preparation Requirements
For extract-based testing (indirect method), samples are typically extracted at a ratio of 0.1g material per 5 mL of extraction vehicle (e.g., 0.9% sodium chloride injection) or according to the surface area of the device. Extraction is performed under standardized conditions, commonly 37°C for a specified duration ranging from 30 minutes to 72 hours depending on the clinical use scenario. For direct contact testing, the device or material is incubated directly with diluted blood under conditions simulating clinical use. All samples must be sterilized using the same method intended for the final product to ensure the evaluation reflects actual use conditions.
Testing Items
The hemolysis test evaluates the following key parameters and endpoints:
- Hemolysis rate (hemolysis index) — the primary quantitative endpoint expressed as a percentage
- Free hemoglobin concentration — measured spectrophotometrically in the supernatant
- Plasma-free hemoglobin — assessed to determine the extent of red blood cell damage
- Erythrocyte morphology — microscopic examination of red blood cell shape changes post-exposure
- Comparison with positive control (complete hemolysis) and negative control (no hemolysis)
The regulatory acceptance criterion for medical device hemolysis testing is typically a hemolysis rate of less than 5%. This threshold is widely accepted by regulatory bodies including those following GB/T 16886.4 (Chinese national standard equivalent to ISO 10993-4), FDA guidance, and European regulatory frameworks. A hemolysis rate exceeding 5% indicates that the device material has unacceptable blood-damaging potential and requires material reformulation or design modification.
Testing Methods
Direct Contact Method
The direct contact method involves incubating the test sample directly with anticoagulated blood. In this approach, fresh rabbit or human blood is diluted with saline, and the test material is added at a defined ratio. The mixture is incubated at 37°C for a specified period (typically 30 to 120 minutes). Following incubation, the samples are centrifuged to separate intact red blood cells from the supernatant. The absorbance of the supernatant is then measured spectrophotometrically at a wavelength of approximately 545 nm (the absorption maximum of hemoglobin). The hemolysis rate is calculated using the formula: Hemolysis Rate (%) = [(OD test − OD negative control) / (OD positive control − OD negative control)] × 100%.
Indirect (Extraction) Method
The indirect method is appropriate for devices where blood contact occurs through leachable substances or for devices with complex geometries that cannot be directly immersed in blood. Test samples are first extracted in an appropriate vehicle such as 0.9% sodium chloride solution, phosphate-buffered saline, or water for injection. The extraction is performed under accelerated or exaggerated conditions (e.g., 37°C, 50°C, or 70°C) to maximize the recovery of potential hemolytic leachables. The resulting extract is then mixed with diluted blood, incubated, centrifuged, and analyzed for free hemoglobin as described above.
Supplementary Hemocompatibility Tests
Hemolysis testing is often performed as part of a broader hemocompatibility panel that may include:
- Thrombosis testing — evaluating thrombus formation on device surfaces
- Coagulation assays — prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT)
- Platelet counting and platelet activation markers
- Complement activation (C3a, C5a) testing
- Leukocyte counting and activation
The selection of supplementary tests depends on the device's blood contact category and intended use duration as defined in ISO 10993-4.
Applications
Hemolysis testing serves multiple critical functions throughout the medical device lifecycle:
- Material screening and selection during research and development phases
- Biological safety evaluation for regulatory submissions (NMPA, FDA, CE marking under MDR)
- Quality control and batch release testing for blood-contacting consumables
- Post-market surveillance and investigation of adverse events
- Equivalence demonstration for material or supplier changes
- Compliance verification for ISO 10993-4 and GB/T 16886.4 requirements
Common device categories requiring hemolysis testing include hemodialysis equipment, cardiopulmonary bypass circuits, blood collection and administration sets, intravenous catheters, cardiac assist devices, oxygenators, and apheresis systems. Manufacturers of these devices must conduct hemolysis testing in accredited third-party laboratories or qualified in-house facilities to support their biological safety documentation for market approval.
FAQ
What is the acceptable hemolysis rate for medical devices?
The widely accepted regulatory threshold for medical device hemolysis is a hemolysis rate below 5%. This criterion is consistent across major regulatory frameworks and is based on the understanding that a hemolysis rate under 5% indicates minimal clinically significant red blood cell damage. Devices exceeding this threshold are considered to pose an unacceptable risk to patients and typically require material or design modification before regulatory approval.
Which standard governs medical device hemolysis testing?
The primary standard is ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood). In China, the equivalent standard is GB/T 16886.4. Additionally, ASTM F756 (Standard Practice for Assessment of Hemolytic Properties of Materials) provides detailed methodology for material-level hemolysis evaluation. These standards specify test selection criteria, methodology guidelines, and reporting requirements for blood-device interaction testing.
What type of blood is used for hemolysis testing?
Fresh anticoagulated rabbit blood is the most commonly used test system for medical device hemolysis testing, particularly when following GB/T 16886.4 methodology. Human blood from healthy donors may also be used, especially when following ASTM F756 or ISO 10993-4 methodologies. The blood must be freshly collected (typically used within a specified timeframe after collection) and diluted appropriately with saline or phosphate-buffered solution to ensure sensitivity and reproducibility of the test.
What is the difference between direct and indirect hemolysis testing?
Direct hemolysis testing involves incubating the device or material sample directly with diluted blood, simulating direct blood contact scenarios. Indirect hemolysis testing first prepares an extract of the device materials in a suitable vehicle, then exposes blood to this extract, evaluating the hemolytic potential of leachable substances. The choice between methods depends on the nature of blood contact during clinical use, with direct testing preferred for devices in prolonged contact with circulating blood and indirect testing suitable for devices with indirect or transient blood contact.
How long does hemolysis testing take?
The complete hemolysis test procedure, including sample preparation, extraction (if applicable), incubation, spectrophotometric analysis, and report generation, typically takes 5 to 10 working days. This timeline may be extended if extraction conditions require longer durations (e.g., 72-hour extraction) or if repeat testing is needed. Manufacturers should plan hemolysis testing early in their regulatory timeline to avoid delays in submission.
Can hemolysis testing be combined with other biocompatibility tests?
Yes, hemolysis testing is frequently performed as part of a comprehensive biocompatibility evaluation program that may include cytotoxicity (ISO 10993-5), sensitization (ISO 10993-10), irritation (ISO 10993-23), and systemic toxicity (ISO 10993-11) testing. Combining tests within a single laboratory program can improve efficiency, reduce sample requirements, and ensure consistent testing conditions across the biological safety assessment.